Genflow Biosciences Plc (GB:GENF) has released an update.
Genflow Bioscience Plc, a biotech firm focusing on longevity research, has reported progress in pre-clinical stages with FDA advisory support and partnerships with Exothera S.A for manufacturing and various Contract Research Organizations for clinical trials. The company is advancing its lead drug candidate GF-1004, aimed at treating age-related diseases, and has received FDA endorsement to pursue further pre-clinical studies. Genflow’s CEO, Dr. Eric Leire, expresses optimism on the company’s trajectory in improving healthspan through their therapeutic solutions.
For further insights into GB:GENF stock, check out TipRanks’ Stock Analysis page.
